Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: A phase 1 trial

Journal of Medical Virology

Volumn 78, Issue 6, 2006, Pages 711-718

  Ide, Fuyuaki ^a   Nakamura, Tetsuya ^a   Tomizawa, Mariko ^a   Kawana Tachikawa, Ai ^a   Odawara, Takashi ^a   Hosoya, Noriaki ^a   Iwamoto, Aikichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

HAART; HIV 1; Treatment interruption; Vaccine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; EFAVIRENZ; GAMMA INTERFERON; HLA A ANTIGEN; LAMIVUDINE; LIVER ENZYME; NELFINAVIR; STAVUDINE; SYNTHETIC PEPTIDE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DETERIORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; LIVER DYSFUNCTION; LYMPHADENOPATHY; MALAISE; MALE; PHASE 1 CLINICAL TRIAL; SUBCUTANEOUS HEMORRHAGE; SWELLING; THROMBOCYTOPENIA; TREATMENT INTERRUPTION; TREATMENT WITHDRAWAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DENDRITIC CELLS; DRUG RESISTANCE, VIRAL; EPITOPES, T-LYMPHOCYTE; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MUTATION; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646480371     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20612     Document Type: Article

References (34)

1. Banchereau J, Palucka AK. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296-306.
2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. 2000. Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811.
3. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. Virus-specific CD8 cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103-6110.
4. Bostrom AC, Hejdeman B, Matsuda R, Fredriksson M, Fredriksson EL, Bratt G, Sandstrom E, Wahren B. 2004. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). Vaccine 22:1683-1691.
5. Dorrell L, Dong T, Ogg GS, Lister S, McAdam S, Rostron T, Conlon C, McMichael AJ, Rowland-Jones SL. 1999. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol 73:1708-1714.
6. Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B, Swiss HIV Cohort Study. 2003. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 163:1220-1226.
7. Foung SK, Taidi B, Ness D, Grumet FC. 1986. A monoclonal antibody against HLA-A11 and A24. Hum Immunol 15:316-319.
8. Furutsuki T, Hosoya N, Kawana-Tachikawa A, Tomizawa M, Odawara T, Goto M, Kitamura Y, Nakamura T, Kelleher AD, Cooper DA, Iwamoto A. 2004. Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese population. J Virol 78:8437-8445.
9. Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, Alos L, Ruiz A, Setoain J, Fumero E, Castro P, Lopez A, Cruceta A, Piera C, Florence E, Pereira A, Libois A, Gonzalez N, Guila M, Caballero M, Lomena F, Joseph J, Miro JM, Pumarola T, Plana M, Gatell JM, Gallart T. 2005. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 191:1680-1685.
10. Harrer E, Bauerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, Handley A, Tzatzaris M, Vollmar J, Bergmann S, Rittmaier M, Eismann K, Muller S, Kalden JR, Spriewald B, Willbold D, Harrer T. 2005. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: Safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10:285-300.
11. Hejdeman B, Leandersson AC, Fredriksson EL, Sandstrom E, Wahren B, Bratt G. 2003. Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up. HIV Med 4:101-110.
12. Ikeda-Moore Y, Tomiyama H, Miwa K, Oka S, Iwamoto A, Kaneko Y, Takiguchi M. 1997. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: Strong epitopes are derived from V regions of HIV-1. J Immunol 159:6242-6252.
13. Ikeda-Moore Y, Tomiyama H, Ibe M, Oka S, Miwa K, Kaneko Y, Takiguchi M. 1998. Identification of a novel HLA-A24-restricted cytotoxic T-lymphocyte epitope derived from HIV-1 Gag protein. AIDS 12:2073-2074.
14. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, Wagner BS, Kaufe ET, Strick D, Rosenberg ES, Walker BD. 2004. Limited durability of viral control following treated acute HIV infection. PLoS Med 1:e36.
15. Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A. 2003. Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. J Immunol 170:4260-4266.
16. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, Goh LE, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard PM, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper DA, Perrin L, QUEST Study Group. 2005. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 192:607-617.
17. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650-4655.
18. + T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 98:1872-1881.
19. + T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 17:2015-2023.
20. Lee Sp, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. 1997. Conserved CTL epitopes within EBV latent membrane protein 2. J Immunol 158:3325-3334.
21. Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, Lewis MG, Wagner W, Pistorio A, Arya S, Lori F. 2005. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 19: 35-43.
22. Lu W, Arraes LC, Ferreira WT, Andrieu JM. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10: 1359-1365.
23. McMichael AJ, Rowland-Jones SL. 2001. Cellular immune responses to HIV. Nature 410:980-987.
24. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, Weber R, Hirschel B, Kostrikis LG, Gunthard HF, The Swiss HIV Cohort Study. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 188:1433-1443.
25. Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, Garcia F, Hirschel B, McLean A, Phillips RE. 2002. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 99:13747-13752.
26. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD. 2000. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6:82-85.
27. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. 2002. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 16:2342-2344.
28. + T cells. Nat Med 9:727-728.
29. Tanaka H, Akaza T, Juji T. 1996. Report of the Japanese Central Bone Marrow Data Center. Clin Transpl 139-144.
30. Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, Sax PE, Walker BD, Hirsch MS, Rosenberg ES, D'Aquila RT. 2003. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS 17:1086-1089.
31. Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Chermak A, Rabian C, Vittecoq D, Simon A, Bouvet E, El Habib R, Costagliola D, Calvez V, Autran B, Katlama C, the Vacciter Study group. 2005. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 23: 4292-4301.
32. Watanabe N, Tomizawa M, Tachikawa-Kawana A, Goto M, Ajisawa A, Nakamura T, Iwamoto A. 2001. Quantitative and qualitative abnormalities in HIV-1-specific T cells. AIDS 15:711-715.
33. Wu L, Kong WP, Nabel GJ. 2005. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 79:8024-8031.
34. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. 2004. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979.